Last reviewed · How we verify
Testosterone cyclopentylpropionate
Testosterone cyclopentylpropionate is a Small molecule drug developed by Parc de Salut Mar. It is currently in Phase 1 development. Also known as: Testex prolongatum®.
Testosterone cyclopentylpropionate is an androgen receptor agonist, classified as a small molecule agonist. It is used in the treatment of various conditions, including prostate cancer, as indicated by clinical trials on ClinicalTrials.gov.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Testosterone cyclopentylpropionate |
|---|---|
| Also known as | Testex prolongatum® |
| Sponsor | Parc de Salut Mar |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer (PHASE2)
- Hormone Secretion in Transgender Males (PHASE4)
- COMbination of Bipolar Androgen Therapy and Nivolumab (PHASE2)
- Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers. (PHASE1)
- CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Testosterone cyclopentylpropionate CI brief — competitive landscape report
- Testosterone cyclopentylpropionate updates RSS · CI watch RSS
- Parc de Salut Mar portfolio CI
Frequently asked questions about Testosterone cyclopentylpropionate
What is Testosterone cyclopentylpropionate?
Who makes Testosterone cyclopentylpropionate?
Is Testosterone cyclopentylpropionate also known as anything else?
What development phase is Testosterone cyclopentylpropionate in?
Related
- Manufacturer: Parc de Salut Mar — full pipeline
- Also known as: Testex prolongatum®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing